<DOC>
	<DOCNO>NCT00121251</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose sorafenib , gemcitabine , capecitabine see well work treat patient unresectable and/or metastatic kidney cancer . Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , gemcitabine capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving sorafenib together gemcitabine capecitabine may kill tumor cell .</brief_summary>
	<brief_title>Sorafenib , Gemcitabine , Capecitabine Treating Patients With Unresectable and/or Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) sorafenib administer combination gemictabine capecitabine patient advance renal cell carcinoma . II . Determine objective response rate sorafenib combination gemictabine capecitabine patient advance renal cell carcinoma . III . Determine duration overall survival progression free survival patient . OUTLINE : This multicenter , non-randomized , phase I dose-escalation study follow phase II study . PHASE I : Patients receive sorafenib* orally ( PO ) twice daily ( BID ) day 1-21 , gemcitabine intravenously ( IV ) 30 minute day 1 8 , capecitabine PO BID day 1-14 . Treatment repeat every 21 day least 3 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos sorafenib , gemcitabine , capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . An additional 6 patient treated MTD . Note : *Patients complete least 3 course treatment objective response stable disease deem poor candidate continue chemotherapy may continue treatment sorafenib PHASE II : Patients receive sorafenib , gemcitabine , capecitabine phase I MTD determine phase I . After completion study treatment patient follow periodically .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must histologically cytologically confirm renal cell carcinoma unresectable and/or metastatic ; patient collect duct carcinoma , oncocytomas , transitional cell carcinoma eligible ; patient sarcomatoid renal cell carcinoma eligible , pure sarcoma ; histologic documentation metastatic disease require ; clinical confirmation , pathologic staging , metastatic disease require Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; = 20 mm conventional technique &gt; = 10 mm spiral compute tomography ( CT ) scan Patients may receive one prior immunotherapy base regimen ( i.e . interleukin2 interferon alpha ) end &gt; = 4 week prior enrollment Patients may receive 2 prior regimen contain mitogenactivated protein kinase ( MAPK ) , vascular endothelial growth factor ( VEGF ) pathway inhibitor ( e.g . sunitinib bevacizumab ) and/or mammalian target rapamycin ( mTOR ) inhibitor ( e.g . temsirolimus ) end &gt; = 4 week prior enrollment Life expectancy 3 month Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 OR Karnofsky &gt; = 60 % Leukocytes &gt; = 3000/uL Absolute neutrophil count &gt; = 1,500/uL Platelet count &gt; = 100,000/uL Total bilirubin = &lt; 1.5 x institutional upper limit normal ( IULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x IULN Creatinine = &lt; 1.5 x IULN OR creatinine clearance &gt; = 60 mL/min/1.73m^2 patient creatinine level institutional normal The effect sorafenib develop human fetus recommend therapeutic dose unknown ; reason raf kinase inhibitor agent well therapeutic agent use trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients may receive prior chemotherapy ; patient prior definitive surgery , prior radiation therapy , must fully recover effect therapy least 4 week recovery time ; patient surgical biopsy , must simply recover Patients may receive investigational agent Patients know active brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event ; previously treat brain metastasis allow show evidence progression CT magnetic resonance imaging ( MRI ) least 8 week completion surgery and/or radiotherapy History allergic reaction attribute compound similar chemical biologic composition sorafenib , gemcitabine capecitabine No concurrent megestrol permit ; megestrol therapy within 4 week prior protocol treatment allow ; concurrent cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , phenobarbitol carbamazepine ) , rifampin , St. John 's wort Uncontrolled intercurrent illness include , limited , uncontrolled hypertension , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , pulmonary disease include asthma , chronic bronchitis , emphysema requirement chronic oxygen use psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study sorafenib kinase inhibitor agent potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother sorafenib , breastfeed discontinue mother treated sorafenib ; potential risk may apply agent use study Because patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , human immunodeficiency virus ( HIV ) positive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction sorafenib , gemcitabine , capecitabine administer study ; appropriate study undertake patient receive combination antretroviral therapy indicate Any swallow dysfunction lead difficulty take investigational therapy capecitabine Prior treatment sorafenib Patients history evidence bleed diathesis Patients therapeutic anticoagulation coumarins ( e.g . warfarin ) ; prophylactic coumarinbased anticoagulation ( i.e . low dose warfarin ) venous arterial access device allow provided requirement prothrombin time ( PT ) , international normalization ratio ( INR ) and/or partial thromboplastin time ( PTT ) meet ; prophylactic therapeutic low molecular weight heparin allow ; patient know brain metastasis exclude ( even treat stable ) also therapeutic dos anticoagulation Patients know dihydropyrimidine dehydrogenase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>